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The tumor microenvironment has profound effects on cancer development, progression, and
therapeutic response. Cancer cells co-exist with infiltrated immune cells, blood vessels, fibroblasts,
and other stromal cells in the tumor microenvironment [1]. Deviated from their normal physiological
roles, immune, vascular, and stromal cells in a tumor are often dysfunctional and exploited by
cancer cells to promote tumor progression. Additionally, biochemical and biophysical characteristics
of the tumor microenvironment are distinct from that in normal tissues. Several hallmarks of the
tumor microenvironment, including hypoxia, acidosis, high interstitial fluid pressure, and increased
extracellular matrix (ECM) stiffness, have been identified [2–7]. As initially proposed in the “seed
and soil” hypothesis by Stephen Paget more than a century ago, tissue microenvironment is critical
for cancer metastasis [8,9]. It has also been demonstrated that microenvironmental factors play
important roles in multiple stages of cancer progression and in the modulation of cancer therapeutic
responses [2–7]. Therapeutics targeting crucial components of the tumor microenvironment, such as
blood vessels and immune cells, have been added to the arsenals of cancer therapy [1,3,10].
The metabolism of cancer cells is reprogrammed from that of normal cells. In the early twentieth
century, Otto Warburg observed that cancer cells preferentially utilize glycolysis, instead of oxidative
phosphorylation, for energy metabolism even in the presence of oxygen (now known as the “Warburg
effect”) [11,12]. Glycolytic metabolism of glucose results in lactic acid, which can acidify the tumor
microenvironment after being expelled by cancer cells [2,4,5]. Moreover, tumor-associated hypoxia
can further increase cellular glycolysis as well as lactic acid production and accumulation in the tumor
microenvironment due to rapid cancer growth and defective blood vessel perfusion. Acidosis and
hypoxia are biochemical hallmarks of the tumor microenvironment and profoundly modulate cancer
cell metabolism and disease progression [2,4,5]. In addition to glucose, cancer cells also utilize lipids,
amino acids, and other substrates for metabolism and biosynthesis. Cancer cell metabolism has been
exploited as a target for cancer treatment [6,13,14].
The purpose of the Special Issue “Tumor Microenvironment and Metabolism” published in
the International Journal of Molecular Sciences is to illustrate some recent development in the field of
tumor microenvironment and cancer cell metabolism. Overall research topics presented include the
tumor microenvironment, hypoxia, acidosis, angiogenesis/anti-angiogenesis therapy, inflammation,
chemokines/other cellular factors, metastasis, tumor immunity/cancer immunotherapy, glycolysis,
lipid metabolism, and one-carbon metabolism of cancer cells.
In the issue, several papers discuss hypoxia, acidosis, and other chemico-physical aspects of
the tumor microenvironment. The review by Koizume and Miyagi discusses tumor hypoxia and the
formation of lipid droplets, a cellular organelle, as a mechanism to promote cancer cell survival in the
microenvironment [15]. Deep and Schlaepfer review the effects of hypoxia on lipid metabolism in
prostate cancer [16]. Bendinelli et al. discuss the roles of hypoxia in cancer bone metastasis, focusing on
the molecular pathways of SPARC (secreted protein acidic and rich in cysteine), Runx2, Endothelin-1,
HGF (hepatocyte growth factor), and HIF-1α (hypoxia inducible factor 1α) [17]. The research article
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by Maeda et al. reports that CD133, a cancer stem cell marker, regulates HIF-1α expression under
hypoxia and promotes migration and epithelial mesenchymal transition (EMT) of pancreatic cancer
cells [18]. In addition to the papers on hypoxia, the research article by Dong et al. describes the
effects of acidosis on vascular endothelial cells and demonstrates that acidosis stimulates endoplasmic
reticulum (ER) stress response pathways through the pH-sensing receptor GPR4 (G protein-coupled
receptor 4) in endothelial cells [19]. The research article by Lin et al. reports that a reduction of
mitochondrial DNA copy numbers in renal cancer cells results in decreased mitochondrial respiration,
increased glycolysis, augmented cell invasion, and resistance to chemotherapeutic drug doxorubicin
in vitro [20]. Russo et al. present findings to show that the ribosomal protein uL3 functions as a
regulator of oxidative stress responses and can re-sensitize multidrug-resistant lung cancer cells
to chemotherapeutics [21]. Moreover, biophysical aspects of the tumor microenvironment are also
discussed. Wang et al. review the rigidity and structural stability of extracellular matrix in the
tumor microenvironment, focusing on the roles of lysyl oxidase (LOX) in crosslinking collagen and
elastin by oxidation, maintaining ECM rigidity and stability, and regulating cancer cell invasion
and metastasis [22]. The research article by Riwaldt et al. describes the effects of microgravity on
gene expression in spheroid formation of thyroid cancer cells and reveals the involvement of several
pathways, such as VEGF (vascular endothelial growth factor), MMPs (matrix metalloproteinases), and
actin, which regulate the rigidity of cytoskeletal proteins and the level of extracellular proteins [23].
Angiogenesis is critical for tumor growth and metastasis. However, blood vessels in a tumor are
often structurally and functionally defective, which is a contributing factor to hypoxia and acidosis in
the tumor microenvironment [1,3,5]. The review by Simone et al. summarizes the molecular pathways
important for angiogenesis and discusses pre-clinical studies and clinical trials of anti-angiogenic drugs
in biliary tract cancer [24]. Angiolini and Cavallaro review the general aspects of tumor angiogenesis
and anti-angiogenic therapy in cancer and then emphasize the role of the adhesion molecule L1CAM
(L1 cell adhesion molecule) in tumor angiogenesis [25]. Guo et al. report the role of mast cell tryptase
(MCT) in pancreatic cancer angiogenesis and demonstrate that MCT stimulates angiogenesis through
upregulating angiopoietin-1 expression and the MCT inhibitor nafamostat exhibits anti-angiogenic
activities [26]. The research article by Cao et al. reveals that the transcription factor Runx2 promotes
vasculogenic mimicry of hepatocellular carcinoma cells (HCC) and increases the EMT, migration, and
invasion of HCC [27].
Tumors are abnormal organ-like structures comprised of multiple cell types and extracellular
matrix [1,3]. Cell–cell interactions through autocrine and paracrine signals play important roles
in tumor growth and metastasis. Itatani et al. discuss the role of chemokines in the invasion and
metastasis of colorectal cancer, focusing on chemokines and their receptors expressed by cancer cells
and bone marrow-derived cells (BMDC) recruited to the tumor microenvironment [28]. Ji reviews the
involvement of chemokines and growth factors in lymph node metastasis of cancer [29]. The research
article by Han et al. reports that tissue factor (TF) produced by lung cancer cells in the tumor
microenvironment stimulates complement activation, myeloid-derived suppressor cell (MDSC)
recruitment, and tumor growth in the xenograft mouse model [30]. Apart from soluble factors,
Roma-Rodrigues et al. review the role of exosomes, a type of nanovesicles produced by cancer
cells, in tumorigenesis and discuss emerging technologies to exploit gold nanoparticles targeting
malicious exosomes for cancer therapy [31]. The research article by Xue et al. demonstrates that CAPS1
(calcium-dependent activator protein for secretion 1) inhibits tumor growth by modulating vesicle
exocytosis of hepatocellular carcinoma (HCC) cells and loss of CAPS1 expression in HCC tissues
is associated with poor overall survival of patients [32]. Moreover, Tahmasebi Birgani and Carloni
use the tumor microenvironment of hepatocellular carcinoma as an example to review the roles of
major signaling pathways and cancer-associated cellular components, such as inflammatory cells,
vascular cells, and stromal cells, in tumorigenesis and cancer therapy [33]. Binnemars-Postma et al.
focus on the biology of tumor-associated macrophages (TAM) and discuss current strategies of
using nanoparticles to target TAM for therapeutic purpose [34]. Additionally, the research article
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by Visser et al. characterizes the immune cell components in the altered microenvironment of
nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), revealing decreases in CD20+
B cells and CD56+ natural killer cells and an increase in CD4+ T cells in NLPHL in comparison
to reactive lymph nodes (RLN) [35]. The fundamental aspects of cancer immunotherapy have
also been discussed. Recent development of immune checkpoint blockade against CTLA-4 and
PD-1/PD-L1 has resulted in the improvement of overall survival in a subset of cancer patients [10].
Botti et al. discuss the heterogeneous expression of PD-L1 in solid tumors and emphasize on
the importance of standardizing PD-L1 immunohistochemistry of tumor tissue microarrays as a
prognostic biomarker [36]. Additionally, Du et al. discuss the need to rationally target multiple
immune checkpoint pathways for cancer treatment, focusing on the immunoregulatory roles of TIM-3
(T cell immunoglobulin and mucin domain 3) [37].
As described earlier, aerobic glycolysis (the Warburg effect) is a common feature observed
in many types of cancer cells [6,11–13]. Recent studies have also demonstrated that, in addition
to glucose, cancer cells utilize multiple sources of substrates, such as lipids and amino acids, for
energetic metabolism and some of the metabolic intermediates are also used by cancer cells for
biosynthesis [6,13,14]. Deep and Schlaepfer discuss the aberrant lipid metabolism in prostate cancer,
focusing on de novo lipid synthesis of cancer cells, lipid oxidation that supports cancer cell proliferation
and survival, and the effects of hypoxia on lipid metabolism in prostate cancer [16]. The review by
Moore and Pidgeon describes the role of bioactive lipids, 5-hydroxyeicosatetraenoic acid (5-HETE) and
leukotrienes, and the 5-lipoxygenase enzyme in immune regulation, angiogenesis, as well as the pro-
and anti-tumorigenic effects of the 5-lipoxygenase/bioactive lipid signaling pathways in cancer [38].
Koizume and Miyagi discuss the formation of lipid droplets in cancer cells as a mechanism for cancer
cells to adapt to stress conditions, such as hypoxia, in the tumor microenvironment [15]. The research
article by Notarnicola et al. reports that dietaryω-3 polyunsaturated fatty acids (ω-3 PUFAs) inhibits
intestinal polyp growth in ApcMin/+ mice, which is correlated with the upregulation of cannabinoid
receptor-1 (CB1) [39].
Additionally, cancer cells depend on one-carbon metabolism, such as the folate and methionine
cycles, for the maintenance of DNA synthesis, epigenetic regulation, and redox homeostasis [40].
Corbin and Ruiz-Echevarría review the major pathways involved in one-carbon metabolism and
discuss the role of androgen signaling in the regulation of one-carbon metabolism as well as DNA
and histone epigenetic methylation in prostate cancer [41]. Parfett and Desaulniers describe the Tox21
approach to assess alterations of multiple epigenetic pathways in carcinogen-induced oncogenesis [42].
The research article by Lopomo et al. investigates the DNA methylation status of genes involved
in one-carbon metabolism (MTHFR) and DNA methylation (DNMT1, DNMT3A, and DNMT3B)
and reveals an increase of MTHFR promoter methylation in thymomas obtained from patients with
myasthenia gravis [43]. Moreover, the research article by Wu et al. examines genetic polymorphisms
related to one-carbon metabolism and vitamin B6 in a cohort of Chinese breast cancer patients,
demonstrating that the polymorphisms of genes involved in one-carbon metabolism are associated
with breast cancer susceptibility and that vitamin B6 deficiency can induce genomic instability in
cultured cells [44].
In summary, the papers published in the Special Issue address multiple facets of tumor
microenvironment and metabolism. The interesting topics discussed range from biomolecular
aspects, such as hypoxia, acidosis, the Warburg effect, cancer cell metabolism, oxidative stress,
extracellular matrix, chemokines, cytokines, growth factors, and signaling pathways, to cellular
aspects, such as angiogenesis, immune cells, stromal cells, cancer cell growth, and metastasis.
Chemotherapy and immunotherapy targeting the tumor microenvironment and metabolism have also
been reviewed. We would like to thank all the authors for their contributions. The goal of the issue
is to stimulate research and discussion in the growing field of tumor microenvironment and cancer
cell metabolism. The importance of tumor microenvironment in oncogenesis is now increasingly
recognized. Cancer cells do not exist in isolation; instead they co-exist with vascular cells, immune
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cells, and stromal cells in a distinct, complex microenvironment [1]. Cancer cell metabolism is also
very distinct from the metabolism of normal cells [6,13]. Equally complex is the reciprocal crosstalk
between cancer cells, stromal cells, and the tumor microenvironment. Co-evolution and adaptation
of cancer cells to the tumor microenvironment play critical roles in regulating disease progression
and therapeutic response. Recent research development prompts us to revisit the “seed and soil”
hypothesis originally proposed by Stephen Paget more than a century ago [8]. Mounting evidence
suggest that targeting both the “seed” (cancer cells) and the “soil” (tumor microenvironment) can be
advantageous for cancer therapy [2–7]. The development of anti-angiogenesis therapy and cancer
immunotherapy is a testament to this concept [1,3,7,10,45]. Despite significant research progresses,
the complex interactions between cancer cells, metabolism, and the tumor microenvironment are
not fully understood. For instance, multiplex inhibitory signals in the tumor microenvironment
that hinder cancer immunotherapy are still ill-defined. Future research to better understand tumor
microenvironment and cancer cell metabolism will prove to be beneficial for a comprehensive
elucidation of tumor biology and the improvement of cancer therapy.
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